Jazz sees sales surge as demand for CBD-based epilepsy drug grows

2 May 2025

US biotech Jazz Pharmaceuticals (Nasdaq: JAZZ) is banking on continued growth from Epidiolex (cannabidiol), the first plant-derived CBD medicine approved by the US regulator to treat seizures linked to rare epilepsies.

The drug pulled in nearly $1 billion in sales last year, and analysts at DelveInsight, which has authored a report on the company’s improving prospects, expect the trend to hold.

Epidiolex is used to treat Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients aged one and up. It remains the only FDA-approved prescription cannabidiol on the market, a status that underscores its position in a fast-moving but still uneven therapeutic category.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical